Carbonic Anhydrase IX Inhibitors as Candidates for Combination Therapy of Solid Tumors.
adjuvant agents
carbonic anhydrase IX
small-molecule inhibitors
solid tumors
tumor acidosis combination cancer therapy
tumor hypoxia
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Dec 2021
14 Dec 2021
Historique:
received:
23
11
2021
revised:
07
12
2021
accepted:
10
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
12
1
2022
Statut:
epublish
Résumé
Combination therapy is becoming imperative for the treatment of many cancers, as it provides a higher chance of avoiding drug resistance and tumor recurrence. Among the resistance-conferring factors, the tumor microenvironment plays a major role, and therefore, represents a viable target for adjuvant therapeutic agents. Thus, hypoxia and extracellular acidosis are known to select for the most aggressive and resilient phenotypes and build poorly responsive regions of the tumor mass. Carbonic anhydrase (CA, EC 4.2.1.1) IX isoform is a surficial zinc metalloenzyme that is proven to play a central role in regulating intra and extracellular pH, as well as modulating invasion and metastasis processes. With its strong association and distribution in various tumor tissues and well-known druggability, this protein holds great promise as a target to pharmacologically interfere with the tumor microenvironment by using drug combination regimens. In the present review, we summarized recent publications revealing the potential of CA IX inhibitors to intensify cancer chemotherapy and overcome drug resistance in preclinical settings.
Identifiants
pubmed: 34948200
pii: ijms222413405
doi: 10.3390/ijms222413405
pmc: PMC8705727
pii:
doi:
Substances chimiques
Carbonic Anhydrase Inhibitors
0
Carbonic Anhydrase IX
EC 4.2.1.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Russian Science Foundation
ID : 21-73-20264
Références
Cancer Immunol Res. 2019 Jul;7(7):1064-1078
pubmed: 31088846
J Enzyme Inhib Med Chem. 2013 Apr;28(2):360-9
pubmed: 23163664
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4681-5
pubmed: 22721713
Tumour Biol. 2016 Jul;37(7):9023-35
pubmed: 26762407
Cancer Res. 2009 Jan 1;69(1):358-68
pubmed: 19118021
Sci Adv. 2021 Aug 27;7(35):
pubmed: 34452919
Clin Epigenetics. 2015 Sep 18;7:102
pubmed: 26388957
Cancer Discov. 2016 Mar;6(3):256-69
pubmed: 26715642
J Biol Chem. 2009 Jul 24;284(30):20299-310
pubmed: 19458084
Mol Cancer Ther. 2011 Sep;10(9):1698-708
pubmed: 21700832
Target Oncol. 2016 Apr;11(2):209-27
pubmed: 26453055
Lancet Haematol. 2020 Nov;7(11):e838-e850
pubmed: 33091357
Bioorg Med Chem Lett. 2003 Mar 24;13(6):1005-9
pubmed: 12643899
Semin Oncol. 2019 Feb;46(1):28-38
pubmed: 30638624
J Transl Med. 2015 Nov 24;13:368
pubmed: 26597250
J Med Chem. 2012 Jun 14;55(11):5591-600
pubmed: 22621623
Radiother Oncol. 2013 Sep;108(3):523-8
pubmed: 23849171
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Mol Cell Biol. 2009 May;29(10):2570-81
pubmed: 19273585
Curr Oncol. 2021 Feb 03;28(1):783-799
pubmed: 33546228
Cancer Metastasis Rev. 2019 Jun;38(1-2):205-222
pubmed: 30911978
Mol Pharm. 2011 Dec 5;8(6):2032-8
pubmed: 21981633
Invest Ophthalmol Vis Sci. 2009 Jan;50(1):345-51
pubmed: 18757514
Br J Cancer. 2008 Jan 29;98(2):418-25
pubmed: 18087285
Cancers (Basel). 2020 May 18;12(5):
pubmed: 32443471
Bioorg Med Chem. 2017 May 1;25(9):2569-2576
pubmed: 28347633
Arch Pharm Res. 2020 Apr;43(4):371-384
pubmed: 32152852
Metabolites. 2017 Dec 23;8(1):
pubmed: 29295495
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Oncologist. 2007 Oct;12(10):1247-52
pubmed: 17962618
Antioxid Redox Signal. 2009 Mar;11(3):601-20
pubmed: 18976116
Cancer Metastasis Rev. 2019 Jun;38(1-2):149-155
pubmed: 30806853
Blood Adv. 2020 May 26;4(10):2286-2296
pubmed: 32453838
BMC Cancer. 2013 Aug 08;13:378
pubmed: 23927827
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Biochem Pharmacol. 2003 Oct 1;66(7):1207-18
pubmed: 14505800
Molecules. 2018 Apr 30;23(5):
pubmed: 29710858
Int J Mol Sci. 2013 May 29;14(6):11402-23
pubmed: 23759990
Bioessays. 2016 Nov;38(11):1102-1110
pubmed: 27717012
Radiother Oncol. 2011 Jun;99(3):424-31
pubmed: 21676479
BMC Cancer. 2019 Aug 30;19(1):864
pubmed: 31470802
J Cell Biochem. 2012 Jul;113(7):2474-87
pubmed: 22396185
J Transl Med. 2010 Jun 15;8:57
pubmed: 20550689
Metabolites. 2018 Feb 28;8(1):
pubmed: 29495652
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13
pubmed: 15547183
JCI Insight. 2017 Dec 21;2(24):
pubmed: 29263302
Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L941-9
pubmed: 16766575
N Engl J Med. 2018 Nov 22;379(21):2052-2062
pubmed: 30462943
Cancer Lett. 2009 Jan 8;273(1):140-7
pubmed: 18778892
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Sci Rep. 2018 Sep 13;8(1):13759
pubmed: 30214007
Int J Mol Sci. 2020 Jul 15;21(14):
pubmed: 32679833
J Enzyme Inhib Med Chem. 2003 Oct;18(5):403-6
pubmed: 14692506
FEBS Lett. 2004 Nov 19;577(3):439-45
pubmed: 15556624
PLoS One. 2016 Aug 11;11(8):e0161040
pubmed: 27513947
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781344
Mol Cancer Ther. 2016 Nov;15(11):2722-2732
pubmed: 27535970
Proc Natl Acad Sci U S A. 1982 Jul;79(13):3935-9
pubmed: 6287453
Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77
pubmed: 21921921
Mol Cancer Ther. 2010 Feb;9(2):336-46
pubmed: 20124447
Nutrients. 2018 Jun 06;10(6):
pubmed: 29882797
Oncotarget. 2015 Sep 22;6(28):24856-70
pubmed: 26259239
J Hematol Oncol. 2016 Sep 06;9(1):83
pubmed: 27601007
Dermatol Clin. 2017 Jan;35(1):51-60
pubmed: 27890237
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Curr Opin Oncol. 2000 Sep;12(5):412-8
pubmed: 10975547
Target Oncol. 2011 Mar;6(1):17-27
pubmed: 21547705
Gastroenterology. 2019 Sep;157(3):823-837
pubmed: 31078621
J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123
pubmed: 30362384
Toxicol Appl Pharmacol. 2017 Feb 1;316:123-138
pubmed: 28038999
Curr Pharm Des. 2009;15(4):436-47
pubmed: 19199971
Theranostics. 2017 Sep 26;7(17):4322-4339
pubmed: 29158829
Int J Mol Sci. 2020 Mar 18;21(6):
pubmed: 32197371
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1439-44
pubmed: 21940327
Chem Biol Interact. 2021 Jan 5;333:109326
pubmed: 33245928
Int J Cancer. 2018 Jan 1;142(1):191-201
pubmed: 28905987
Oxid Med Cell Longev. 2018 Jun 6;2018:5438179
pubmed: 29977456
Future Oncol. 2014 May;10(7):1215-37
pubmed: 24947262
Oncol Lett. 2018 Jun;15(6):9299-9306
pubmed: 29928333
Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84
pubmed: 15664816
PLoS Genet. 2008 Dec;4(12):e1000293
pubmed: 19057672
J Cell Mol Med. 2010 Apr;14(4):771-94
pubmed: 20015196
J Enzyme Inhib Med Chem. 2016;31(sup1):119-125
pubmed: 27142956
Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33
pubmed: 16039848
Cancer Res. 2008 Jul 1;68(13):5487-91
pubmed: 18593952
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
BMC Cancer. 2017 Feb 24;17(1):156
pubmed: 28235409
Cancers (Basel). 2019 Jul 17;11(7):
pubmed: 31319613
Expert Opin Investig Drugs. 2018 Dec;27(12):963-970
pubmed: 30426805
J Transl Med. 2016 Nov 22;14(1):323
pubmed: 27876058
Oncotarget. 2016 Jun 14;7(24):36666-36680
pubmed: 27153561
Oncol Lett. 2021 May;21(5):369
pubmed: 33747225
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1906-1922
pubmed: 33078634
Oncotarget. 2018 Sep 21;9(74):33982-33994
pubmed: 30338040
Br J Cancer. 2020 Jan;122(2):157-167
pubmed: 31819195
Am J Clin Oncol. 2020 Jul;43(7):484-490
pubmed: 32251122
Med Res Rev. 2020 Nov;40(6):2485-2565
pubmed: 32691504
J Enzyme Inhib Med Chem. 2020 Dec;35(1):391-397
pubmed: 31865754
Anticancer Agents Med Chem. 2010 Sep;10(7):571-81
pubmed: 20812900